BioPharmSignal logoBioPharmSignal

Biotech News

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

Synlogic (SYBX)SynlogicEarnings

CAMBRIDGE, Mass. , March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023 .

Related news

VANIVivani Medical2026-03-26 20:16 EST

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

MISTMilestone Pharmaceuticals Inc.2026-03-20 11:55 EST

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

MISTMilestone Pharmaceuticals Inc.2026-03-12 12:00 EST

Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

MLYSMineralys Therapeutics2026-03-12 20:05 EST

Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

ALGSAligos Therapeutics2026-08-06 12:00 EST

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

MNKDMannKind2026-08-05 20:01 EST

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

ALTAltimmune2026-08-05 12:00 EST

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

MLYSMineralys Therapeutics2026-08-04 12:00 EST

Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026

VKTXViking Therapeutics2026-07-29 20:05 EST

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Synlogic

Synlogic was a synthetic-biology company focused on engineered microbes and metabolic disease before its restructuring and decline. Its platform aimed to use living medicines to address rare disorders.

Recent company news

SYBXSynlogic2026-07-29 11:00 EST

Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement

SYBXSynlogic2024-11-12 21:35 EST

Synlogic Reports Third Quarter 2024 Financial Results

SYBXSynlogic2024-08-08 11:00 EST

Synlogic Reports Second Quarter 2024 Financial Results

SYBXSynlogic2024-05-14 11:00 EST

Synlogic Reports First Quarter 2024 Financial Results

SYBXSynlogic2024-03-19 11:00 EST

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

Stock data

Close
1.20 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States